GlaxoSmithKline PLC (GSK): Price and Financial Metrics
GlaxoSmithKline PLC (GSK)
Today's Latest Price: $36.04 USD
Updated Oct 20 7:00pm
Add GSK to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
GSK Stock Summary
- With a market capitalization of $97,380,319,359, Glaxosmithkline Plc has a greater market value than 98.15% of US stocks.
- GSK's went public 34.31 years ago, making it older than 92.41% of listed US stocks we're tracking.
- The volatility of Glaxosmithkline Plc's share price is greater than that of only 1.94% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to GSK, based on their financial statements, market capitalization, and price volatility, are MMM, CAT, IBM, PDD, and ZTS.
- GSK's SEC filings can be seen here. And to visit Glaxosmithkline Plc's official web site, go to www.gsk.com.
GSK Stock Price Chart Interactive Chart >
GSK Price/Volume Stats
| Current price | $36.04 | 52-week high | $48.25 |
| Prev. close | $36.18 | 52-week low | $31.43 |
| Day low | $35.78 | Volume | 5,306,397 |
| Day high | $36.24 | Avg. volume | 3,770,184 |
| 50-day MA | $38.74 | Dividend yield | 5.36% |
| 200-day MA | $40.87 | Market Cap | 90.41B |
GlaxoSmithKline PLC (GSK) Company Bio
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The companys wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.
GSK Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $36.04 | $21.74 | -40% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Glaxosmithkline Plc. To summarize, we found that Glaxosmithkline Plc ranked in the 34th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Glaxosmithkline Plc, consider:
- The company has produced more trailing twelve month cash flow than 93.01% of its sector Healthcare.
- Glaxosmithkline Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 24.08% of tickers in our DCF set.
- GSK's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than merely 24.08% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -41% |
| 1% | -41% |
| 2% | -40% |
| 3% | -39% |
| 4% | -39% |
| 5% | -38% |
Want more companies with a valuation profile/forecast similar to that of Glaxosmithkline Plc? See CRL, ENDP, IQV, MD, and PRGO.
Loading social stream, please wait...